Recombinant Human TNFSF14 protein, His-Flag-tagged
Cat.No. : | TNFSF14-144H |
Product Overview : | Human LIGHT is expressed from HEK293 with a His tag and Flag Tag at the N-terminal. It contains Asp74-Val240 Trimer Design. |
- Specification
- Gene Information
- Related Products
- Download
Description : | LIGHT, also known as tumor necrosis factor superfamily member 14 (TNFSF14), is a secreted protein of the TNF superfamily. It is recognized by herpesvirus entry mediator (HVEM), as well as decoy receptor 3.This protein has been shown to stimulate the proliferation of T cells, and trigger apoptosis of various tumor cells. |
Source : | HEK293 |
Species : | Human |
Tag : | His&Flag |
Form : | Supplied as 0.22um filtered solution in PBS (pH 7.4). |
Molecular Mass : | The protein has a predicted MW of 52.4kDa.Due to glycosylation, the protein migrates to 52- 140KDa based on Bis-Tris PAGE result. |
Protein length : | It contains Asp74-Val240 Trimer Design. |
Endotoxin : | Less than 0.05EU per ug by the LAL method. |
Purity : | > 95% as determined by SDS-PAGE |
Storage : | The product should be stored at -70°C. Please do not repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Gene Name : | TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens ] |
Official Symbol : | TNFSF14 |
Synonyms : | CD258 antigen; CD258;TNFSF14; delta transmembrane LIGHTHerpes virus entry mediator ligand; Herpesvirus entry mediator ligand; HVEM-L; HVEMLherpesvirus entry mediator-ligand; ligand for herpesvirus entry mediator; LIGHT; LIGHTherpesvirus entry mediator A; LTg; TR2; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT |
Gene ID : | 8740 |
mRNA Refseq : | NM_003807 |
Protein Refseq : | NP_003798 |
MIM : | 604520 |
UniProt ID : | O43557 |
Products Types
◆ Recombinant Protein | ||
Tnfsf14-147M | Recombinant Mouse Tnfsf14 Protein | +Inquiry |
TNFSF14-303H | Active Recombinant Human TNFSF14 Protein (Arg64-Val240), C-His tagged, Animal-free, Carrier-free | +Inquiry |
TNFSF14-1324H | Acitve Recombinant Human TNFSF14 protein(Asp74-Val240), rFc-tagged | +Inquiry |
TNFSF14-1544M | Recombinant Mouse TNFSF14 Protein, His-tagged | +Inquiry |
TNFSF14-783C | Recombinant Cynomolgus Monkey TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
TNFSF14-891HCL | Recombinant Human TNFSF14 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThe extended longevity of results gave us the confidence to delve deeper into complex biological processes.
It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.
The ability to obtain enduring results positively influenced the depth of our investigations.
Q&As (7)
Ask a questionTNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.
While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.
TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.
TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.
TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.
TNFSF14 has been in pre-clinical development for over a decade.
TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.
Ask a Question for All TNFSF14 Products
Required fields are marked with *
My Review for All TNFSF14 Products
Required fields are marked with *
Inquiry Basket